References
- Acevedo R, Bai X, Borrow R, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30.
- Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.
- Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–20.
- Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498.
- Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782.
- Olbrich KJ, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–438.
- Harrison LH, Granoff DM, Pollard AJ. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Plotkin’s vaccines: Philadelphia, Elsevier, 2018. p. 619–643.
- Pollard AJ, Goldblatt D. Immune response and host-pathogen interactions. Methods Mol Med. 2001;66:23–39.
- Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10). DOI:https://doi.org/10.3390/microorganisms8101521
- Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–29.
- Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–67.
- Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ. 2002;324(7341):809.
- Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5(3):220–225.
- Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–847.
- Maiden MCJ, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743.
- Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336(7659):1487–1491.
- Findlow H, Campbell H, Lucidarme J, et al. Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. Euro Surveill. 2019;24(1):1700818.
- Joint Committee on Vaccination and Immunisation (JCVI). Minute of the meeting on 4 February 2015. [cited 2021 Feb 2]. Available from: http://app.box.com/s/iddfb4ppwkmtjusir2tc/file/229171832189.
- Public Health England. Historical vaccine development and introduction of routine vaccine programmes in the UK. 2019. [cited 2021 Feb 2]. Available from: http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/816174/Vaccine_Timeline_2019.pdf.
- Public Health England. Immunisation against infection disease. Chapter 22. Meningococcal. 2016. [cited 2021 Jan 21]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/554011/Green_Book_Chapter_22.pdf.
- European Centre for Disease Prevention and Control. Disease data from ECDC Surveillance Atlas for meningococcal disease. 2020 Feb. [cited 2021 Feb 2]. Available from: http://www.ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas.
- Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2019 to 2020. 2021 Jan. Available from: http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/951142/hpr0121_imd-ann.pdf.
- Welte R, van den Dobbelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making. Vaccine. 2004;23(4):470–479.
- De Greeff SC, de Melker HE, Spanjaard L, et al. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. Ned Tijdschr Geneeskd. 2003;147(23):1132–1135.
- National Institute for Public Health and the Environment. The National Immunisation Programme in the Netherlands. Developments in 2012. RIVM report 201001002/2012. [cited 2021 Feb 2]. Available from: http://www.rivm.nl/bibliotheek/rapporten/201001002.pdf.
- De Greeff SC, de Melker HE, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25(1):79–80.
- Bijlsma MW, Brouwer MC, Spanjaard L, et al. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis. 2014;59(9):1216–1221.
- National Institute for Public Health and the Environment. The national immunisation programme in the Netherlands. Surveillance and developments in 2018-2019. 2019. [cited 2021 Feb 2]. Available from: http://www.rivm.nl/bibliotheek/rapporten/2019-0193.pdf.
- Kremastinou J, Tzanakaki G, Kansouzidou A, et al. Recent emergence of serogroup C meningococcal disease in Greece. FEMS Immunol Med Microbiol. 1999;23(1):49–55.
- Kafetzis DA, Stamboulidis KN, Tzanakaki G, et al. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect. 2007;13(5):550–552.
- Flountzi A, Georgakopoulou T, Balasegaram S, et al. Epidemiology of invasive meningococcal disease in Greece, 2006-2016. Eur J Clin Microbiol Infect Dis. 2019;38(12):2197–2203.
- De Waure C, Miglietta A, Nedovic D, et al. Reduction in Neisseria meningitidis infection in Italy after meningococcal C conjugate vaccine introduction: a time trend analysis of 1994-2012 series. Hum Vaccin Immunother. 2016;12(2):467–473.
- Pezzotti P, Miglietta A, Neri A, et al. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. Vaccine. 2018;36(29):4222–4227.
- Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C/clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12):30176.
- Bennett D, O’Lorcain P, Morgan S, et al. Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016. Epidemiol Infect. 2019;147:e142.
- Health Protection Surveillance Center. Bacterial meningitis/Meningococcal disease. 2019 Sept. [cited 2021 Feb 2]. Available from: http://www.hpsc.ie/a-z/vaccinepreventable/bacterialmeningitis/factsheets/#:~:text=Group%20C%3A%20The%20meningococcal%20group,2%2C%204%20and%206%20months
- Maoldomhnaigh C, Drew RJ, Gavin P, et al. Invasive meningococcal disease in children in Ireland, 2001-2011. Arch Dis Child. 2016;101(12):1125–1129.
- Taha MK, Gaudelus J, Deghmane AE, et al. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother. 2020;16(10):2518-2523. DOI:https://doi.org/10.1080/21645515.2020.1729030
- Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad CyBS. Grupo de trabajo vacunación frente a EMI de la Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de vacunación frente a enfermedad meningocócica invasiva. 2019 March. [cited 2021 Feb 2]. Available from: http://www.mscbs.gob.es/va/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf.
- Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034–2041.
- Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14):1800245.
- Abad R, Vázquez JA. Early evidence of expanding W ST-11 CC meningococcal incidence in Spain. J Infect. 2016;73(3):296–297.
- Hong E, Barret AS, Terrade A, et al. Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France. J Infect. 2018;76(2):149–158.
- Loenenbach AD, van der Ende A, de Melker HE, et al. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015-2018. Clin Infect Dis. 2020;70(10):2036–2044.
- Stinson C, Burman C, Presa J, et al. Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci. Epidemiol Infect. 2020;148:e12.
- European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC. 2019. [cited 2021 Feb 2]. Available from: http://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf.
- Campbell H, Edelstein M, Andrews N, et al. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016. Emerg Infect Dis. 2017;23(7):1184–1187.
- Health Ministry Italy. Piano nazionale prevenzione vaccinale PNPV 2017-2019. 2017 Jan. [cited 2021 Feb 2]. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf.
- National Immunisation Office. MenACWY schools immunisation program. 2020 Aug. [cited 2021 Feb 2]. Available from: http://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/menacwy/.
- Ladhani SN, Ramsay M, Borrow R, et al. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91–95.
- Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334–1346.
- Department of Health and Social Care, Public Health England. JCVI position statement on use of Bexsero meningococcal B vaccine in the UK. 2014 March. [cited 2021 Feb 22]. Available from: http://www.gov.uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement.
- Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
- Moore JE. Meningococcal disease section 2: epidemiology and vaccination of meningococcal disease in Northern Ireland: MeningoNI Forum. Ulster Med J. 2018;87(2):88–93.
- Signorelli C, Odone A, Cella P, et al. Childhood vaccine coverage in Italy after the new law on mandatory immunization. Ann Ig. 2018;30(4Suppl 1):1–10.
- Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against Group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014–2018). Vaccines (Basel). 2020;8(3):469.
- National Immunisation Office. Primary childhood immunisation schedule. Disease vaccines prevent - Meningococcal B. 2019 Jan. Available from: http://www.hse.ie/eng/health/immunisation/pubinfo/pcischedule/vpds/menb/.
- Mulhall RM, Bennett D, Cunney R, et al. Potential coverage of the 4CMenB Vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland. mSphere. 2018;3(4):e00196–00118.
- Rodrigues FMP, Marlow R, Simões MJ, et al. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–2194.
- Office of the Secretary of State for Health, Portugal. Despacho n.º 12434/2019. Diario da Republica. Series 2, 2019. Available from: https://dre.pt/application/conteudo/127608823.
- Haute Autorité de Santé. Stratégie de vaccination pour la prévention des infections invasives à méningocoques: Le sérogroupe B et la place de Bexsero®. June 2021. [cited 2021 Jul 19]. Available from: http://www.has-sante.fr/upload/docs/application/pdf/2021-06/strategie_de_vaccination_pour_la_prevention_des_infections_invasives_a_meningocoques_le_serogroupe_b_et_la_place_de_bexsero.pdf.
- World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. 2020 Oct. [cited 2021 Feb 2]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules.
- Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005;23(19):2470–2476.
- Campbell H, Andrews N, Parikh S, et al. Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England. J Infect. 2020;80(2):182–189.
- Guiddir T, Gros M, Hong E, et al. Unusual initial abdominal presentations of invasive meningococcal disease. Clin Infect Dis. 2018;67(8):1220–1227.
- McMillan M, Wang B, Koehler AP, et al. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73:e233–e237.
- Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641–658.
- Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38(47):7558–7568.
- European Medicines Agency. Bexsero: summary of product characteristics. 2020 Jul. [cited 2021 Feb 2]. Available from: http://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf.
- Macias Parra M, Gentile A, Vazquez Narvaez JA, et al. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: a phase 3b, randomized controlled trial. Vaccine. 2018;36(50):7609–7617.
- Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–2510.
- Welsch JA, Senders S, Essink B, et al. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018;36(35):5309–5317.
- Borrow R, Taha MK, Giuliani MM, et al. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020;81(6):862–872.
- Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–7550.
- Biolchi A, Tomei S, Brunelli B, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2020. DOI:https://doi.org/10.1007/s40121-020-00370-x.
- Hong E, Giuliani MM, Deghmane AE, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31(7):1113–1116.
- Leduc I, Connolly KL, Begum A, et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 2020;16(12):e1008602.
- Ladhani SN, Campbell H, Andrews N, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa1244.
- Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.
- Marshall HS, Maiden MCJ. The impact of a meningococcal protein-based serogroup B vaccine on serogroup W invasive disease in children. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa1253
- Alderson MR, LaForce FM, Sobanjo-Ter Meulen A, et al. Eliminating meningococcal epidemics from the African meningitis belt: the case for advanced prevention and control using next-generation meningococcal conjugate vaccines. J Infect Dis. 2019;220(Suppl 4):S274–S278.